Moreover, another PARPi, namely talazoparib, already showed promising neoadjuvant efficacy in gBRCA-mutant TNBC49 and the same olaparib is currently under evaluation in a phase II study in monotherapy or in combination with the immune-checkpoint inhibitor durvalumab in early-stage HER2-negative BC with either a germline or somatic BRCA1/2 mutations (OlimpiaN, ClinicalTrials.gov identifier: NCT05498155). This evidence concerns the gene BRCA1 and breast cancer.